



Erratum

To cite this article: (2011) Erratum, Expert Opinion on Pharmacotherapy, 12:13, 2143-2143, DOI: [10.1517/14656566.2011.609055](https://doi.org/10.1517/14656566.2011.609055)

To link to this article: <https://doi.org/10.1517/14656566.2011.609055>



Published online: 06 Aug 2011.



Submit your article to this journal [↗](#)



Article views: 330



View related articles [↗](#)

In the article, “An adjusted indirect comparison of everolimus and sorafenib therapy in sunitinib-refractory metastatic renal cell carcinoma patients using repeated matched samples”, by Di Lorenzo *et al.* (*Expert Opin Pharmacother* 2011;12(10):1491-1497), an error has been identified. In the Abstract, the sentence, “After adjusted matching, the estimated median OS benefit is 32.7 weeks (95% CI: 22, 64) and 81.5 weeks (95% CI: 78, 86) for sorafenib and everolimus patients, respectively”, should read, “After adjusted matching, the estimated median OS benefit is 32.0 weeks (95% CI: 22, 64) and 81.5 weeks (95% CI: 78, 86) for sorafenib and everolimus patients, respectively.” In the Results section, the sentence, “Overall, the everolimus data resulted in a clinically meaningful increase in median OS relative to the sorafenib data, with median OS estimates of 81.5 weeks (95% CI: 78, 86) for the everolimus population and 32.7 weeks (95% CI: 22, 64) for the sorafenib population (Table 2)”, should read, “Overall, the everolimus data resulted in a clinically meaningful increase in median OS relative to the sorafenib data, with median OS estimates of 81.5 weeks (95% CI: 78, 86) for the everolimus population and 32.0 weeks (95% CI: 22, 64) for the sorafenib population (Table 2).”

Informa Healthcare and the authors of this article would like to apologize for any confusion caused.